AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05004181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)
Study NCT05004181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.1.7)
Description: Intramuscular (IM)
Study NCT05004181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.617.2)
Description: Intramuscular (IM)
Study NCT05004181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.1.529.1)
Description: Intramuscular (IM)
Study NCT05004181 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: No vaccination within 3 months after Visit 1.
Study NCT06651879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: techniques of ultrasound examination of the airway
Description: two different techniques of ultrasound. The techniques are the two views and the five views
Study NCT06651879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: techniques of ultrasound examination of the airway
Description: two different techniques of ultrasound. The techniques are the two views and the five views
Study NCT06649825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Vitamin B1 tablets, 100mg bid, taken orally for one year
Study NCT05334108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam
Description: ecopipam HCl \~2mg/kg/day
Study NCT05334108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 1 Probe Substrate Cocktail
Description: dextromethorphan, caffeine, omeprazole, and midazolam
Study NCT05334108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 2 Probe Substrate
Description: bupropion
Study NCT05334108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 3 Probe Substrate Cocktail
Description: dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
Study NCT05544968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
Description: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
Study NCT06649799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenSx
Description: The patients in Group 1 conduct FLACS under LenSx
Study NCT06649799 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Z8
Description: The patients in Group 1 conducted FLACS using Z8
Study NCT06652620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cola
Description: regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
Study NCT06652685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5-PBCR(-) IA arm
Description: Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Study NCT06652685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5-PBCR(+) IA+Venetoclax arm
Description: Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Study NCT06652347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer care delivery
Description: Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: 2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day for 5 days
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 60 mg/kg/day for 2 days in cord blood stem cell transplantation
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 2mg/m2/day for 3 days in cord blood stem cell transplantation
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg/dose every 12 hours
Study NCT05303727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
Study NCT05103410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARIPiprazole 30 MG
Description: Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
Study NCT05103410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
Study NCT05164562 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Description: musculoskeletal disorders of upper limb evaluation
Study NCT05005130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASKPEN
Description: TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)
Study NCT04917198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median sternotomy
Description: median sternotomy
Study NCT06520748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand rehabilitation program using the computerized glove
Description: The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
Study NCT06520748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected hand program
Description: Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
Study NCT06536010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
Description: VAG in the induction phase of the ND-AML treatment protocol
Study NCT05239026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced treadmill walking
Description: Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
Study NCT05239026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional treadmill walking
Description: Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
Study NCT04736576 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
Study NCT05584839 — intervention group
Intervention type: OTHER
Intervention: Statistically Analysis
Description: The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
Study NCT06662435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GYNCOG
Description: Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours.
Study NCT05598619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Colon delivered vitamin C (ascorbic acid) for 12 weeks
Study NCT06498856 — intervention group
Intervention type: OTHER
Intervention: Isotonic saline infusion
Description: Volume expansion with one liter of isotonic saline intravenously over two hours.
Study NCT06511635 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Interview between participant and a researcher, in order to identity the determinants of participation in a clinical trial among participants in the CMVictory vaccine trial.
Study NCT06511635 — intervention group
Intervention type: OTHER
Intervention: Quantitative questionnaire
Description: Anonymous online survey using a 3-part questionnaire, studying knowledge of clinical research and the determinants of participation in a preventive vaccine study in a population of young women (aged 18-40).
Study NCT05738733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Classic Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.
Study NCT05738733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Ylang Ylang Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.
Study NCT05738733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Vanilla & Citrus Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.
Study NCT05738733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Tea & Peach Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.
Study NCT05395260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101
Description: FL-101 200mg IV
Study NCT06323837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.
Study NCT06323837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match.
Study NCT04992078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIO/CORI Surgical System
Description: Unicompartmental knee replacement with robotic assistance
Study NCT04992078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-robotic conventional instrumentation
Description: Unicompartmental knee replacement with non-robotic conventional instrumentation
Study NCT05598619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Colon delivered placebo once a day for 12 weeks
Study NCT05813730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: urinary creatinine excretion measurement
Description: Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
Study NCT05771077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly(Amidoamine) dendrimer
Description: to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite \& Their Combination on demineralized enamel \& Their Clinical Efficacy on White Spot lesion
Study NCT04704310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing exercise training for adults with COPD: The roles of peers and functional tasks
Description: A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
Study NCT05611983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory relearning
Description: feasibility of early sensory relearning
Study NCT05359263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: The intervention arm consists of dapagliflozin 10 mg orally once daily
Study NCT05359263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator arm consists of placebo orally once daily
Study NCT04700241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate
Description: Acute intervention (5.5 hours)
Study NCT04700241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute intervention (5.5 hours)
Study NCT06663995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Group
Description: It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy
Study NCT06663995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
Study NCT06664281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIT
Description: sprint interval training
Study NCT06664281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIT combined RIPC
Description: sprint interval training combined with remote ischemic preconditioning
Study NCT06663059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.
Study NCT06663059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.
Study NCT06663891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI with EEG per MRI
Description: 2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,
Study NCT06661109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention (Kinesio Taping) group
Description: No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
Study NCT06661109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention (Kinesio Taping) group
Description: No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
Study NCT06663878 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MWAV201
Description: Nonreplicating, recombinant gene transfer vector